Hello Everyone. I am not a writer by Trade, but I hope I do this info. I am about to provide U some Justice. Sat. August 16, 2014 I volunteered my services to The NYC Black Pride Health & Culture Expo. & I learned some important things. Did U know they have a drug called Prep. It helps U from contracting HIV.

I found out at the Expo. NO was one has informed ME about this Drug because I am not what the government considers a High Risk to contract HIV. Do U know what the government consider a high risk?:

Having UnProtected Intercourse on a Regular.

Gay.

Since I don't fit under their guide lines they believe I should not be informed that there is a Drug that can save Ur & MY Life. This is NOT Fair and I want to Inform the World.

Please Read ON.

Truvada is the first drug approved by the FDA for the prevention of HIV infection. Known as PrEP (short for pre-exposure prophylaxis), this treatment is meant to be employed alongside other risk-reduction measures, such as safer sex and regular HIV testing; however, it has caused some controversy, both among medical experts and in communities of men who sleep with men—the group hardest hit by HIV in the United States.

Pre-exposure prophylaxis is any medical or public health procedure used before exposure to the disease causing agent, its purpose is to prevent, rather than treat or cure a disease. An example would be if a doctor gave a medication used to treat a disease to a healthy person who is not thought to have that disease, but is at risk for contracting it. More specifically, this practice is common with people who are about to travel from an area without malaria to an area where malaria is a risk. It is also commonly used as a tool to prevent persons from contracting HIV, as is recommended by the CDC.

Pre-exposure prophylaxis for HIV (PrEP)Edit

The terms "pre-exposure prophylaxis" or "PrEP" most commonly refer to an HIV-prevention strategy where antiretrovirals are used to protect HIV-negative people from HIV infection. The HIV antiviral Truvada was approved by the FDA for PrEP on July 16, 2012. The CDC amended its guidelines for HIV prevention recommending pre-exposure prophylaxis with Truvada to high infection risk populations on May 14, 2014, due to research indicating prophylactic effectivity preventing transmission from mother to child. Prior to that date, Truvada was only approved to treat existing HIV infections,

PrEP Studies

Most PrEP studies utilize the drug tenofovir or a tenofovir/emtricitabine combo (Truvada) that is delivered orally. Initial studies of PrEP strategies in non-human primates showed a reduced risk of infection among animals that receive ARVs prior to exposure to a simian form of HIV. A 2007 study at UT-Southwestern (Dallas) and the University of Minnesota showed PrEP to be effective in "humanized" laboratory mice. In 2008, the iPrEx study demonstrated 42% reduction of HIV infection among men who have sex with men, and subsequent study of the data indicated 99% protection with daily adherence.

Adverse effects

The PrEP studies have shown the drugs to be safe, with few side effects. Generally, minor side effects such as nausea or diarrhea resolve themselves within the first few months.[11] Effects of Truvada on kidney function have been shown to be temporary.